ArticleScientific reports2018
Effects of Modulating Actin Dynamics on HER2 Cancer Cell Motility and Metastasis.
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 19 citations in OpenAlex.
- Trisoxazole Macrolides Potentiate the Microtubule Assembly and Antimitotic Activities of Taxanes.Angewandte Chemie (International ed. in English) · 2026Article
- Sequential lymphotoxin-β receptor and retinoic acid receptor signals regulate cDC2 fate.Nature immunology · 2025Article
- Sequential Lymphotoxin Beta Receptor and Retinoic Acid Receptor signals regulate cDC2 fates.Research square · 2025Article
- An Immune-Independent Mode of Action of Tacrolimus in Promoting Human Extravillous Trophoblast Migration Involves Intracellular Calcium Release and F-Actin Cytoskeletal Reorganization.International journal of molecular sciences · 2024Article
- Differential impact of cytoplasmic vs. nuclear RAD51 expression on breast cancer progression and patient prognosis.International journal of oncology · 2024Article
- Development of an Antibody Delivery Method for Cancer Treatment by Combining Ultrasound with Therapeutic Antibody-Modified Nanobubbles Using Fc-Binding Polypeptide.Pharmaceutics · 2022Article
- Morphological features of single cells enable accurate automated classification of cancer from non-cancer cell lines.Scientific reports · 2021Article
- In vitro and in silico anticancer potential analysis of3 Biotech · 2021Article
- The prognostic significance of interferon-stimulated gene 15 (ISG15) in invasive breast cancer.Breast cancer research and treatment · 2021Article
- The histone H2B ubiquitin ligase RNF40 is required for HER2-driven mammary tumorigenesis.Cell death & disease · 2020Article
- Platelet ATP, Thyroid Hormone Receptor on Integrin αvβ3 and Cancer Metastasis.Hormones & cancer · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
Amplification of HER2 leads to development of HER2-positive (HER2+) cancers with high rates of metastasis compared to other cancer subtypes. The goal of this study was to probe the vulnerability of HER2+ cancer cells to a filamentous actin (F-actin) severing and capping toxin. The growth and viability of human HER2+ breast cancer (HCC1954) and ovarian cancer (SKOV3) cell lines were significantly impaired upon treatment with the marine macrolide mycalolide B (Myc B) at doses above 100 nanomolar. Further testing of Myc B in combination with the antibody-drug conjugate Trastuzumab-emtansine (T-DM1) led to improved killing of SKOV3 cells compared to either treatment alone. At sub-lethal doses, treatment of HER2+ cancer cells with Myc B resulted in rapid loss of leading edge protrusions and formation of aggresomes containing F-actin and the actin regulatory protein Cortactin. This correlated with robust inhibition of HER2+ cancer cell motility and invasion with Myc B treatment. In SKOV3 tumor xenograft assays, intratumoral injections of Myc B impaired HER2+ tumor growth and metastasis, with maximal effects observed in combination with systemic delivery of Trastuzumab. Metastasis of SKOV3 cells to the lungs following tail vein injection was also reduced by Myc B. Together, these findings provide rationale for targeting F-actin in combination with existing therapies for HER2+ cancers to reduce metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.